Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q99417
UPID:
MYCBP_HUMAN
Alternative names:
Associate of Myc 1
Alternative UPACC:
Q99417; B2R4N0; Q5TA64; Q96HE2
Background:
The c-Myc-binding protein, also known as Associate of Myc 1, plays a crucial role in cellular processes by potentially controlling the transcriptional activity of MYC. It is known to stimulate the activation of E box-dependent transcription, which is pivotal for MYC's function in cell growth, differentiation, and apoptosis.
Therapeutic significance:
Understanding the role of c-Myc-binding protein could open doors to potential therapeutic strategies. Its interaction with MYC, a protein involved in numerous cancers, suggests that targeting this association could offer a novel approach to cancer therapy.